Hanmi Kicks off Sales of Esomezol in the U.S.
Hanmi Kicks off Sales of Esomezol in the U.S.
  • Korea IT Times (info@koreaittimes.com)
  • 승인 2013.12.20 19:19
  • 댓글 0
이 기사를 공유합니다

SEOUL, KOREA - anmi Pharm launched the sales of its in-house-developed reflux esophagitis drug Esomezol in the U.S. market from December 18.

Although Hanmi acquired FDA approval in August, first among Korea’s modified drugs, it took four months for Hanmi to begin the sales of Esomezol in the U.S. due to a patent dispute with multinational drug company Astra Zeneca.

Hanmi Pharm started supplying Esomezol in the U.S. through its partner company Amneal. Esomezol is a new medicine that is created by modifying Astra Zeneca’s reflux esophagitis drug Nexium which has generated annual sales of about $2.3 billion in the U.S. market alone. The price of Esomezol is about 30 percent cheaper than that of Nexium.

Until next May when the patent of Nexium will expire, Esomezol would compete only with Nexium in the U.S. market. Hanmi expects to generate more than 50 billion won in sales during the first year of its entry into the U.S. market.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트